ReiThera, founded in 2005 and headquartered in Rome, Italy, is a biotechnology company specializing in the development and GMP manufacturing of viral vectors for vaccines and gene therapies. The company offers comprehensive services, including process development, technology transfer, and large-scale production of vectors such as adenovirus, AAV, lentivirus, modified vaccinia Ankara (MVA), and herpes simplex virus (HSV). ReiThera's proprietary platforms support the development of genetic vaccines and advanced therapies.